疏血通注射液治疗急性脑梗死的临床效果观察

Clinical effect of Shuxuetong Injection on the treatment of acute cerebral infarction

目的分析急性脑梗死应用疏血通注射液治疗的临床效果及对患者美国国立卫生研究院卒中量表(NIHSS)评分的影响。方法92例急性脑梗死患者,按照就诊顺序分为参照组和研究组,每组46例。参照组患者应用丹参注射液治疗,研究组应用疏血通注射液治疗。比较两组症状积分变化、治疗效果及神经功能缺损情况。结果治疗后,两组症状积分均低于治疗前,且研究组症状积分(5.62±2.37)分低于参照组的(7.34±2.01)分,差异有统计学意义(P<0.05)。研究组治疗总有效率95.65%(44/46)高于参照组的78.26%(36/46),差异有统计学意义(P<0.05)。治疗后,两组NIHSS评分均低于治疗前,且研究组NIHSS评分(10.41±1.03)分低于参照组的(17.06±2.08)分,差异有统计学意义(P<0.05)。结论急性脑梗死使用疏血通注射液治疗可有效改善患者临床症状,降低神经缺损程度,具有临床推广价值。

Objective To analyze the effect of Shuxuetong Injection on the treatment of acute cerebral infarction,and its influence on the National Institutes of Health stroke scale(NIHSS)score.Methods A total of 92 patients with acute cerebral infarction were divided into the reference group and the research group according to the order of treatment,with 46 cases in each group.Patients in the reference group were treated with Danshen Injection,and patients in the research group was treated with Shuxuetong Injection.The changes in symptom scores,therapeutic effects,and neurological deficits were compared between the two groups.Results After treatment,the symptom scores of the two groups were lower than those of this group before treatment,and the symptom score(5.62±2.37)points of the research group was lower than(7.34±2.01)points of the reference group;all the differences were statistically significant(P<0.05).The total effective rate of treatment 95.65%(44/46)in the research group was higher than 78.26%(36/46)in the reference group,and the difference was statistically significant(P<0.05).After treatment,the NIHSS scores of the two groups were lower than those of this group before treatment,and the NIHSS score(10.41±1.03)points of the research group was lower than(17.06±2.08)points of the reference group;all the differences were statistically significant(P<0.05).Conclusion Shuxuetong injection can effectively improve the clinical symptoms of patients with acute cerebral infarction,reduce the degree of nerve defect,and has clinical promotion value.